LWCFA
NVAX icon

Loring Wolcott & Coolidge Fiduciary Advisors’s Novavax NVAX Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.37K Hold
570
– – ﹤0.01% 541
2026
Q1 		$4.63K Hold
570
– – ﹤0.01% 542
2025
Q4 		$5.6K Hold
570
– – ﹤0.01% 514
2025
Q3 		$4.76K Hold
570
– – ﹤0.01% 514
2025
Q2 		$3.59K Hold
570
– – ﹤0.01% 504
2025
Q1 		$4.26K Hold
570
– – ﹤0.01% 511
2024
Q4 		$5.31K Hold
570
– – ﹤0.01% 508
2024
Q3 		$5.65K Hold
570
– – ﹤0.01% 522
2024
Q2 		$9.37K Hold
570
– – ﹤0.01% 492
2024
Q1 		$2.32K Hold
570
– – ﹤0.01% 549
2023
Q4 		$2.28K Hold
570
– – ﹤0.01% 537
2023
Q3 		$4.07K Sell
570
-570
-50% -$4.55K ﹤0.01% 561
2023
Q2 		$8.47K Buy
+1,140
New +$8.96K ﹤0.01% 550

Other funds holding NVAX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
EP
Edgestream Partners Princeton, New Jersey $3.37B AUM 20.71% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's NVAX Position: Q2 2026 in Review

Loring Wolcott & Coolidge Fiduciary Advisors held its Novavax (NVAX) position steady in Q2 2026 at 570 shares worth $5.37K. The position accounts for ﹤0.01% of the portfolio, ranked #541.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in NVAX in Q2 2023 and has held it in 13 quarters since. The position peaked at $9.37K in Q2 2024. 152 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Loring Wolcott & Coolidge Fiduciary Advisors held 570 shares of Novavax worth $5.37K as of Q2 2026.
  • Loring Wolcott & Coolidge Fiduciary Advisors left its Novavax share count unchanged in Q2 2026.
  • Novavax made up ﹤0.01% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #541 holding.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Novavax in Q2 2023 and has held it in 13 quarters since.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Novavax position peaked at $9.37K in Q2 2024.
  • 152 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.